This is a PDF file of a peer-reviewed paper that has been accepted for publication. Although unedited, the content has been subjected to preliminary formatting. Nature Medicine is providing this early version of the typeset paper as a service to our authors and readers. The text and figures will undergo copyediting and a proof review before the paper is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

Background The recent global outbreak of the human monkeypox virus (MPXV) was declared a public health emergency by the World Health Organization. Modified Vaccinia Ankara (MVA) is currently the only FDA-approved vaccine against MPXV that was approved for this indication based on a study in non-human primates. Since there is currently scarce evidence of the efficacy in humans, our objective was to evaluate real-life vaccine effectiveness (VE) after providing one vaccine dose to individuals at risk of MPVX infection. Methods The study cohort included all Clalit Health Services (CHS) members eligible for the MVA vaccine as defined by the Israeli Ministry of Health. The study commenced on July 31, 2022, when the MVA vaccination campaign was initiated in CHS, and participants were followed until September 12, 2022. A Cox proportional-hazards regression model with time-dependent covariates was used to estimate the association between vaccination and MPXV infections with adjustment for sociodemographic and clinical risk factors. Findings A total of 1,970 subjects met the study eligibility criteria (0.04% of CHS members). Of them, 873 (44%) were vaccinated with MVA and completed at least 25 days of follow-up. 18 infections were confirmed in CHS during the study period, 3 in vaccinated and 15 in unvaccinated status (40.0 versus 6.4 per 100,000 person days). VE was estimated at 79% (95% CI: 24%-94%). Interpretation Our results suggest that a single dose of MVA is associated with a significantly lower risk for MPVX infection in high-risk individuals. These findings highlight that urgent MVA vaccination of high-risk individuals may contribute to the containment of the current MPXV outbreak.

BackgroundThe recent global outbreak of the human monkeypox virus (MPXV) was declared a public health emergency by the World Health Organization. Modified Vaccinia Ankara (MVA) is currently the only FDA-approved vaccine against MPXV that was approved for this indication based on a study in non-human primates. Since there is currently scarce evidence of the efficacy in humans, our objective was to evaluate real-life vaccine effectiveness (VE) after providing one vaccine dose to individuals at risk of MPVX infection.MethodsThe study cohort included all Clalit Health Services (CHS) members estimated to be at moderate to high risk for MPXV infection. The study commenced on July 31, 2022, when the MVA vaccination campaign was initiated in CHS, and participants were followed until August 10, 2022. A Cox proportional-hazards regression model with time-dependent covariates was used to estimate the association between vaccination and MPXV infections with adjustment for sociodemographic and clinical risk factors.Results8,168 subjects met the study eligibility criteria (0.17% of CHS members). Of them, 626 (7.7%) were vaccinated with MVA and completed at least 7 days of follow-up. 14 infections were confirmed in CHS during the study period, all within the study cohort and all in unvaccinated participants. VE was estimated at 100% (95% CI: 100%-100%).ConclusionsThese short-term preliminary results suggest a very high VE of a single dose of MVA for MPVX infection in moderate to high-risk individuals. These findings suggest that urgent MVA vaccination of high-risk subjects may contribute to outbreak containment.

Background: The outbreak of the COVID-19 pandemic led to a decrease in primary health care in-person visits and a simultaneous increase in virtual encounters. Objective: To quantify the change in the total volume of primary care visits and mix of visit types during the two years of the pandemic in Israel. Design: Cross-sectional study. Participants: All primary care visits by members of the largest healthcare organization in Israel, during three one-year periods: the pre-COVID-19 year (March 2019–February 2020), the first year of COVID-19 (March 2020–February 2021), and the second year of COVID-19 (March 2021–February 2022). Main measures: Total volume of primary care visits and mix of visit types. Results: More than 112 million primary care visits were included in the study. The total visit rate per 1000 members did not change significantly between the pre-COVID year (19) and the first COVID year (19.8), but was 21% higher in the second COVID-19 year (23). The rate of in-person visits per 1000 members decreased from 12.0 in the pre-COVID year to 7.7 in the first COVID year and then increased to 9.6 in the second. The rate of phone visits and asynchronous communication increased from 0.7 and 6.3, respectively, in the pre-COVID year, to 4.1 and 8, respectively, in the first COVID year, and remained unchanged in the second. There was substantial variation across age groups and sectors in the adoption of virtual platforms. Conclusions: The rapid introduction of virtual encounters in primary care tended to displace in-person visits in the first year of the pandemic, but they appear to have been additive in the second. This transition should be monitored, with the goal of ensuring appropriate planning efforts and resource allocation to deal with the potential added burden on medical staff. Efforts should be invested in encouraging the use of virtual platforms in patient groups that currently underutilize it, such as minorities.

Background The global supply of vaccines against monkeypox virus infection (MPXVi) is significantly lower than demand. Evidence-based vaccine prioritization criteria, based on risk assessment, are essential for fair vaccine distribution. Our objective was to identify the characteristics of individuals at the highest risk for MPXVi. Methods This population-based cohort study included all Clalit Health Services (CHS) subjects assumed to be at risk for MPXVi, based on known characteristics of infected subjects worldwide and insights of LGBTQ+ -specialized CHS clinicians. Cox hazards models were used to identify risk factors for MPXVi in the study cohort. The study commenced on June 6, 2022, the date of the first known MPXVi in CHS patients, until July 31, 2022, when the MPXV vaccination campaign started. Results 8,088 individuals (0.18% of the CHS total population) were identified according to the study inclusion criteria. Of those, 69 (0.85%) were infected during the study period. Risk factors for MPXVi were birth in 1980 or later, history of syphilis, HIV-PrEP use, PDE5 inhibitors use, recent STIs, and registeration to primary healthcare clinics in the Tel-Aviv district. No infections were observed in individuals with none of the factors. Individuals with 3+ risk factors had a 20-fold higher risk for MPXVi compared to those with 0-2, with 85.5% sensitivity and 77.8% specificity. Conclusions Counting the number of validated risk factors per individual seems to provide a robust, simple risk score for MPXVi. Weighting individuals’ risk levels against vaccine availability can assist health systems in the equitable prioritization of vaccine allocation.